Breast Cancer Research and Treatment

, Volume 91, Issue 2, pp 173–178 | Cite as

Metaplastic breast carcinoma: clinical–pathologic characteristics and HER2/neu expression

  • P. J. Barnes
  • R. Boutilier
  • D. Chiasson
  • D. Rayson
Report

Abstract

Background. Metaplastic breast carcinomas (MBC) are rare primary breast malignancies characterized by the co-existence of carcinoma with non-epithelial cellular elements. They can be classified as monophasic spindle cell (sarcomatoid) carcinoma, biphasic carcinosarcoma, adenocarcinoma with divergent stromal differentiation (osseous, chondroid and rarely rhabdoid) as well as adenosquamous and pure squamous cell carcinomas. There is a paucity of information on clinically relevant pathologic features and clinical outcomes for these rare tumors. The aim of this study was to review the pathologic features and clinical outcomes of all cases of MBC seen at a single institution between 1971 and 2000.

Methods. A computerized search of the Queen Elizabeth II Health Sciences Center (QEII HSC) surgical pathology files was performed for the years 1971–2000. Tumor blocks from identified cases were reviewed and immunohistochemistry was performed for estrogen and progesterone receptors (ER/PR), HER2/neu protein overexpression and cytokeratin profile. Clinical outcome information was obtained from hospital files and telephone contact with treating physicians.

Results. Twenty-six (26) cases were retrieved with only one case identified before 1990. All tumors were high grade with a median tumor size of 3.7 cm (range 1.4–9.5 cm). Thirteen cases had lymph node dissections available for evaluation, with 4 demonstrating nodal metastases. Five of 26 cases were ER positive within the adenocarcinomatous component, only two of which also expressed PR. Associated ductal carcinoma in situ (DCIS) was present in 11 cases. HER2/neu over-expression was seen in only one (1/26) adenosquamous carcinoma (3 + membranous staining of the malignant glandular component). At 23 months median follow-up, disease free survival (DFS) for the entire group was 53%.

Conclusions. Although a rare breast cancer subtype, MBC is of considerable interest due to its pathological heterogeneity and differences in clinical behavior compared to typical breast carcinomas. Increasing pathologic recognition of MBC as a discrete entity is suggested by the number of MBC diagnoses in the last decade compared to previous years. The poor DFS associated with MBC suggests that further research exploring mechanisms of carcinogenesis and identifying clinically relevant prognostic factors is needed to direct optimum clinical care. Importantly, MBC variants appear to rarely overexpress the HER2/neu oncoprotein.

Keywords

breast cancer HER2/neu metaplastic 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tavassoli, FA 1992Classification of metaplastic carcinomas of the breastPathol Annual 27 Pt289119Google Scholar
  2. 2.
    Rosen, PP 1997Rosen’s Breast PathologyLippencott-RavenPhiladelphia375395Google Scholar
  3. 3.
    Elston, CW, Ellis, IO 1998The BreastChurchill LivingstoneEdinburg323330Google Scholar
  4. 4.
    Wargotz, ES, Norris, HJ 1989Metaplastic carcinomas of the breast: III. CarcinosarcomaCancer6414901499PubMedGoogle Scholar
  5. 5.
    Wargotz, ES, Deos, PH, Norris, HJ 1989Metaplastic carcinomas of breast: II. Spindle cell carcinomaHum Pathol20732740CrossRefPubMedGoogle Scholar
  6. 6.
    Gutman, H, Pollock, RE, Janjan, NA,  et al. 1995Biological distributions and therapeutic implications of sarcomatoid metaplasia of epithelial carcinoma of the breastJ Am Coll Surg180193199PubMedGoogle Scholar
  7. 7.
    Carter, CL, Allen, C, Henson, DE. 1989Relation of tumor size, lymph node status and survival in 24,740 breast cancer casesCancer63181187PubMedGoogle Scholar
  8. 8.
    Harris, JR, Hellmann, S. 1996

    Natural history of breast cancer

    Harris, JRLippmann, MEMorrow, MHellmann, S eds. Diseases of the BreastLippencott-RavenPA Philadelphia375391
    Google Scholar
  9. 9.
    Rayson, D, Adjei, AA, Suman, VJ,  et al. 1999Metaplastic breast cancer: Prognosis and response to systemic therapyAnnals of Oncol10413419Google Scholar
  10. 10.
    Elston, CW, Ellis, IO 1991Pathologic prognostic factors in breast cancerThe value of histologic grade in breast cancer. Experience from a large study with long term follow-up. Histopathology19403410Google Scholar
  11. 11.
    Oberman, HA 1987Metaplastic carcinoma of the breastAm J Surg Path11351358PubMedGoogle Scholar
  12. 12.
    Foschini, MP, Dina, RE, Eusebi, V. 1993Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomasSeminars in Diag Pathol10128136Google Scholar
  13. 13.
    Wargotz, ES, Norris, HJ 1990Metaplastic carcinomas of the breast: IV. Squamous cell carcinoma of ductal originCancer65272PubMedGoogle Scholar
  14. 14.
    Weidner, N. 1995Malignant breast lesions that may mimic benign tumorsSeminars in Diagn Pathol12213Google Scholar
  15. 15.
    Adem, C, Reynolds, C, Adlakha, H, Roche, PC, Nascimento, AG 2002Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patientsHistopathology40556562PubMedGoogle Scholar
  16. 16.
    Gobbi, H, Simpson, JF, Borowsky, A,  et al. 1999Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrenceCancer8521702182PubMedGoogle Scholar
  17. 17.
    Sneige, N, Yaziji, H, Mandavilli, SR,  et al. 2001Low-grade (fibromatosis-like) spindle cell carcinoma of the breastAm J Surg Pathol2510091016PubMedGoogle Scholar
  18. 18.
    Eusabi, V, Cattan, MG, Ceccarelli, C,  et al. 1989Sarcomatoid carcinoma of the breast: an immunocytochemical study of 14 casesProg Surg Pathol108399Google Scholar
  19. 19.
    Kaufman, MW, Marti, JR, Gallager, HS, Hoehn, JL. 1984Carcinoma of the breast with pseudosarcomatous metaplasiaCancer5319081917PubMedGoogle Scholar
  20. 20.
    Wargotz, ES, Norris, HJ 1989Metaplastic carcinomas of the breast: I. Matrix-producing carcinomaHum Pathol20628635PubMedGoogle Scholar
  21. 21.
    Wargotz, ES, Norris, HJ 1990Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cellsHum Pathol2111421150PubMedGoogle Scholar
  22. 22.
    Park, JM, Han, BK, Moon, WK,  et al. 2000Metaplastic carcinoma of the breast: mammographic and sonographic findingsJ Clin Ultrasound28179186PubMedGoogle Scholar
  23. 23.
    Kurian, KM, Al-Nafussi, A 2002Sarcomatoid/metaplastic carcinoma of the breast: a clinicopathological study of 12 casesHistopathology405864PubMedGoogle Scholar
  24. 24.
    Bellino, R, Arisio, R, D’Addato, F 2003Metaplastic breast carcinoma: pathology and clinical outcomeAnticancer Res23669673PubMedGoogle Scholar
  25. 25.
    Hanna, W, O’Malley, FP 2002Updated recommendations from the HER2/neu consensus meeting- Toronto, Ontario, September 2001Current Oncol9s18s20Google Scholar
  26. 26.
    Pitts, WC, Rojas, VA, Gaffey, MJ,  et al. 1991Carcinoma with metaplasia and sarcomas of the breastAm J Clin Pathol95623632PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • P. J. Barnes
    • 1
  • R. Boutilier
    • 2
  • D. Chiasson
    • 3
  • D. Rayson
    • 3
  1. 1.Department of PathologyQueen Elizabeth II Health Sciences CentreNova ScotiaCanada
  2. 2.Department of PathologyColchester Regional HospitalNova ScotiaCanada
  3. 3.FRCPC, Division of Medical OncologyQueen Elizabeth II Health Sciences CentreNova ScotiaCanada

Personalised recommendations